Denosumab versus zoledronic acid in elderly patients after hip fracture
Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis. The purpose of this study was to evaluate the real-world effectiveness and adherence of denosumab compared to zoledronic acid in geriatric patient...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-12-01
|
| Series: | Journal of Orthopaedic Surgery |
| Online Access: | https://doi.org/10.1177/10225536221147082 |
| _version_ | 1828089530038616064 |
|---|---|
| author | Seung-Ju Kim Ji Woon Kim Dong-Woo Lee |
| author_facet | Seung-Ju Kim Ji Woon Kim Dong-Woo Lee |
| author_sort | Seung-Ju Kim |
| collection | DOAJ |
| description | Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis. The purpose of this study was to evaluate the real-world effectiveness and adherence of denosumab compared to zoledronic acid in geriatric patients after a hip fracture. Methods A total of 282 patients treated with osteoporotic hip fracture between March 2014 and Aug 2022 were retrospectively reviewed. The patients were asked to select the anti-osteoporosis medication after surgery. Treatment persistence was monitored by follow-up visit to the outpatient clinic at postoperative 2 years. Results Of 282 individuals with baseline data, 162 patients took subcutaneous denosumab and 120 patients took intravenous zoledronic acid. At postoperative 2 years, the change in bone mineral density (BMD) from baseline was greater in the denosumab group compared with the zoledronic acid group ( p < 0.001). The rate of persistence to denosumab was significantly higher than that for 12-months zoledronic acid ( p = 0.01). Serious adverse events were similar in the two groups. Conclusions Our study revealed the effectiveness and patients' persistence for two commonly used anti-osteoporosis agents after hip fracture. In this frail, elderly population, half-yearly denosumab was superior to yearly zoledronic acid in BMD and demonstrated significant higher persistence rate, indicating a potential therapeutic advantage that warrants further validation. |
| first_indexed | 2024-04-11T05:43:26Z |
| format | Article |
| id | doaj.art-6ae07cdda17746809f201095f73d1869 |
| institution | Directory Open Access Journal |
| issn | 2309-4990 |
| language | English |
| last_indexed | 2024-04-11T05:43:26Z |
| publishDate | 2022-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Orthopaedic Surgery |
| spelling | doaj.art-6ae07cdda17746809f201095f73d18692022-12-22T04:42:22ZengSAGE PublishingJournal of Orthopaedic Surgery2309-49902022-12-013010.1177/10225536221147082Denosumab versus zoledronic acid in elderly patients after hip fractureSeung-Ju KimJi Woon KimDong-Woo LeeBackground Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis. The purpose of this study was to evaluate the real-world effectiveness and adherence of denosumab compared to zoledronic acid in geriatric patients after a hip fracture. Methods A total of 282 patients treated with osteoporotic hip fracture between March 2014 and Aug 2022 were retrospectively reviewed. The patients were asked to select the anti-osteoporosis medication after surgery. Treatment persistence was monitored by follow-up visit to the outpatient clinic at postoperative 2 years. Results Of 282 individuals with baseline data, 162 patients took subcutaneous denosumab and 120 patients took intravenous zoledronic acid. At postoperative 2 years, the change in bone mineral density (BMD) from baseline was greater in the denosumab group compared with the zoledronic acid group ( p < 0.001). The rate of persistence to denosumab was significantly higher than that for 12-months zoledronic acid ( p = 0.01). Serious adverse events were similar in the two groups. Conclusions Our study revealed the effectiveness and patients' persistence for two commonly used anti-osteoporosis agents after hip fracture. In this frail, elderly population, half-yearly denosumab was superior to yearly zoledronic acid in BMD and demonstrated significant higher persistence rate, indicating a potential therapeutic advantage that warrants further validation.https://doi.org/10.1177/10225536221147082 |
| spellingShingle | Seung-Ju Kim Ji Woon Kim Dong-Woo Lee Denosumab versus zoledronic acid in elderly patients after hip fracture Journal of Orthopaedic Surgery |
| title | Denosumab versus zoledronic acid in elderly patients after hip fracture |
| title_full | Denosumab versus zoledronic acid in elderly patients after hip fracture |
| title_fullStr | Denosumab versus zoledronic acid in elderly patients after hip fracture |
| title_full_unstemmed | Denosumab versus zoledronic acid in elderly patients after hip fracture |
| title_short | Denosumab versus zoledronic acid in elderly patients after hip fracture |
| title_sort | denosumab versus zoledronic acid in elderly patients after hip fracture |
| url | https://doi.org/10.1177/10225536221147082 |
| work_keys_str_mv | AT seungjukim denosumabversuszoledronicacidinelderlypatientsafterhipfracture AT jiwoonkim denosumabversuszoledronicacidinelderlypatientsafterhipfracture AT dongwoolee denosumabversuszoledronicacidinelderlypatientsafterhipfracture |